Droperidol Dosing for PONV
For PONV prophylaxis in adults, use droperidol 0.625-1.25 mg IV, with the maximum initial dose not exceeding 2.5 mg IV according to FDA labeling, though lower doses (0.625-1 mg) are equally effective and safer. 1, 2
Prophylactic Dosing
The optimal prophylactic dose is 0.625-1.25 mg IV administered before emergence from anesthesia:
- 0.625 mg IV is highly effective, reducing PONV incidence from 41% to 7% when given 30 minutes before emergence 3
- 1 mg or less provides excellent antiemetic efficacy with lower risk of adverse effects 2
- Doses above 1 mg offer no additional benefit for nausea prevention and increase adverse effects 4, 2
- The FDA-approved maximum initial dose is 2.5 mg IV, though this higher dose is rarely necessary 1
Dose-Response Characteristics
The antiemetic effects show specific patterns 4, 2:
- For nausea prevention: 0.25-0.30 mg provides short-lived effect (NNT = 5 for early nausea), with no dose-responsiveness beyond this 4
- For vomiting prevention: Dose-responsiveness exists up to 1.5-2.5 mg (NNT = 7 for early vomiting, NNT = 4-6 for late vomiting) 4
- Low-dose efficacy (≤1 mg): RR 0.45 for early nausea, RR 0.65 for early vomiting, RR 0.61 for late vomiting 2
Rescue Treatment Dosing
For established PONV, administer 0.625 mg IV 3, 5:
- Droperidol 0.625 mg is equally effective as ondansetron 4 mg or promethazine 12.5 mg for rescue treatment 3
- However, if droperidol was used for prophylaxis and failed, promethazine (complete response rate 77-78%) is significantly more effective than repeating droperidol (complete response rate 56%) 5
Pediatric Dosing
In children 2-12 years old, the maximum recommended initial dose is 0.1 mg/kg (approximately 75 mcg/kg for optimal efficacy) 1, 4:
- 75 mcg/kg provides best efficacy (NNT = 4 for both early and late vomiting) 4
- Dose-responsiveness is more pronounced in children than adults 4
Critical Safety Considerations
Absolute Contraindications 6, 1:
- Prolonged QTc interval: >440 ms in males, >450 ms in females
- Concomitant use of other QT-prolonging drugs (Class I/III antiarrhythmics, certain antihistamines, antimalarials)
High-Risk Populations Requiring Caution 6, 1:
- Age ≥65 years
- Congestive heart failure
- Bradycardia
- Cardiac hypertrophy
- Hypokalemia or hypomagnesemia
- Diuretic use
- Alcohol abuse
- Hepatic or renal dysfunction (dose reduction recommended) 6
FDA Black Box Warning 6:
The FDA added a black box warning in 2001 indicating droperidol should only be used when first-line drugs are unsuccessful, based on cardiac death risk at high doses (25 mg) in psychiatric patients 6. However, this warning was based on high-dose use, and low-dose droperidol (≤1 mg) remains widely used in clinical practice with excellent safety profile 2.
Adverse Effects
Common adverse effects are dose-dependent 4, 2:
- Sedation/drowsiness: NNT = 7.8 at 2.5 mg dose 4
- Hypotension: Most common complication, occurring in up to 24% of patients 6
- Extrapyramidal symptoms: Rare (NNT for harm = 408 in any patient, 91 in children) 4, 2
- Restlessness: Increased risk compared to placebo 2
- Protective effect against headache: NNT = -25 4
Timing and Duration
- Onset of action: 3-10 minutes 6
- Duration of effect: 2-4 hours 6
- Optimal timing: Administer 30 minutes before emergence from anesthesia for prophylaxis 3
- The duration is shorter than intrathecal morphine effects, so repeated or continuous administration may be needed for prolonged opioid-induced PONV 7
Clinical Context
Droperidol is classified as a first-line antiemetic (dopamine D2 antagonist) alongside 5-HT3 antagonists and dexamethasone 6. Each class provides approximately 25% relative risk reduction when used individually, with multimodal combinations providing superior efficacy 6. For high-risk patients, 2-3 antiemetics from different classes should be used 6.